Detalles de la búsqueda
1.
Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial.
Lancet
; 401(10383): 1172-1182, 2023 04 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36889333
2.
Less bleeding by omitting aspirin in non-ST-segment elevation acute coronary syndrome patients: Rationale and design of the LEGACY study.
Am Heart J
; 265: 114-120, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37517430
3.
An immediate or early invasive strategy in non-ST-elevation acute coronary syndrome: The OPTIMA-2 randomized controlled trial.
Am Heart J
; 234: 42-50, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33422517
4.
Three-year clinical outcomes of the absorb bioresorbable vascular scaffold compared to Xience everolimus-eluting stent in routine PCI in patients with diabetes mellitus-AIDA sub-study.
Catheter Cardiovasc Interv
; 98(4): 713-720, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33118696
5.
Predictors and outcomes of procedural failure of percutaneous coronary intervention of a chronic total occlusion-A subanalysis of the EXPLORE trial.
Catheter Cardiovasc Interv
; 97(6): 1176-1183, 2021 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32294316
6.
One-year mortality in NSTEMI patients is unaffected by timing of PCI within the first week of admission: Results of a real-world cohort analysis.
Catheter Cardiovasc Interv
; 98(5): E661-E667, 2021 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34263520
7.
Bioresorbable Scaffolds versus Metallic Stents in Routine PCI.
N Engl J Med
; 376(24): 2319-2328, 2017 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28402237
8.
Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug-eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease-AIDA trial substudy.
Catheter Cardiovasc Interv
; 95(1): 89-96, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30968559
9.
Recovery and prognostic value of myocardial strain in ST-segment elevation myocardial infarction patients with a concurrent chronic total occlusion.
Eur Radiol
; 30(1): 600-608, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31350585
10.
Exercise testing after chronic total coronary occlusion revascularization in patients with STEMI and a concurrent CTO: A subanalysis of the EXPLORE-trial.
Catheter Cardiovasc Interv
; 94(4): 536-545, 2019 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30968546
11.
Angiographic and clinical outcomes of antegrade versus retrograde techniques for chronic total occlusion revascularizations: Insights from the PRISON IV trial.
Catheter Cardiovasc Interv
; 93(2): E81-E89, 2019 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30280464
12.
Paclitaxel-eluting balloon versus everolimus-eluting stent in patients with diabetes mellitus and in-stent restenosis: Insights from the randomized DARE trial.
Catheter Cardiovasc Interv
; 93(2): 216-221, 2019 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30232824
13.
Scaffold thrombosis following implantation of the ABSORB BVS in routine clinical practice: Insight into possible mechanisms from optical coherence tomography.
Catheter Cardiovasc Interv
; 92(2): E106-E114, 2018 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29332307
14.
Impact of ultra-thin struts on restenosis after chronic total occlusion recanalization: Insights from the randomized PRISON IV trial.
J Interv Cardiol
; 31(5): 580-587, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-29717512
15.
The effect of revascularization of a chronic total coronary occlusion on electrocardiographic variables. A sub-study of the EXPLORE trial.
J Electrocardiol
; 51(5): 906-912, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30177338
16.
Improved recovery of regional left ventricular function after PCI of chronic total occlusion in STEMI patients: a cardiovascular magnetic resonance study of the randomized controlled EXPLORE trial.
J Cardiovasc Magn Reson
; 19(1): 53, 2017 Jul 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-28724418
17.
A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
Lancet
; 385(9962): 43-54, 2015 Jan 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-25230593
18.
REVascularization with paclitaxEL-coated balloon angioplasty versus drug-eluting stenting in acute myocardial infarcTION-A randomized controlled trial: Rationale and design of the REVELATION trial.
Catheter Cardiovasc Interv
; 87(7): 1213-21, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26370515
19.
A prospective, postmarket study with the Mguard Prime Embolic Protection Stent in ST-segment elevation myocardial infarction: the International MGuard Prime Observational Study (IMOS Prime).
Catheter Cardiovasc Interv
; 86 Suppl 1: S28-33, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25754236
20.
Appropriate use of bioresorbable vascular scaffolds in percutaneous coronary interventions: a recommendation from experienced users : A position statement on the use of bioresorbable vascular scaffolds in the Netherlands.
Neth Heart J
; 23(3): 161-5, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25626696